Supplement
AKG (Alpha-Ketoglutarate)
One small aging trial made it famous. The replication has not arrived.
Alpha-ketoglutarate is a molecule involved in the Krebs cycle, the cell's energy production pathway. We grade AKG (Alpha-Ketoglutarate) C+ on evidence and C+ for worth-it at about $25-40 per month.
Evidence
Worth it
Typical cost: $25-40/month
What it does
Alpha-ketoglutarate is a molecule involved in the Krebs cycle, the cell's energy production pathway. Levels decline with age, which sparked interest in supplementing it, usually as calcium AKG.
What the research says
May slow measures of biological aging
Evidence: emerging. One notable human trial reported reduced biological age markers with calcium AKG; small sample, needs replication. Needs verification.
Supports bone density in older adults
Evidence: emerging. Some trials in postmenopausal women suggest benefit; evidence base is small. Needs verification.
Associated with lower biological-age residual in one 2026 cross-sectional study
Evidence: emerging. Aging Cell (May 2026): 143 delayed-release CaAKG users averaged 1.8 years lower age residual vs non-users, significant after adjustment; the longitudinal slice (n=26) was not significant. Regular CaAKG showed an 8x smaller, insignificant effect. Observational, not causal.
DRAFT: best human signal is the 2026 Aging Cell cross-sectional association (1.8-yr lower age residual, n=143, observational); the earlier 42-person retrospective had no control group; the double-blind ABLE RCT is the one to watch. No longevity RCT readout exists.
Is it worth it?
DRAFT: moderate cost against a thin evidence base; the worth-it case depends entirely on future replication.
Typical cost
$25-40/month
Common form, not a brand recommendation
Dosage contextemerging
1 g per day of calcium AKG was used in the notable human trial; no established long-term dosing.
Safety notes
Short-term use appears well tolerated in trials, but long-term safety data in healthy people is limited. Talk to your doctor before supplementing. This page is information, not medical advice.
Longevity Lab Report
AKG (Alpha-Ketoglutarate) news, graded when it happens.
New studies, dose debates, and expert shifts on akg (alpha-ketoglutarate), in one email a week. Free.
Changelog
Last updated 2026-10-15
- 2026-10-15|Seed entry created as DRAFT. All claims need verification against primary trials.
- 2026-10-15|Dosage context added.
- 2026-10-15|Goal tags added for the stack builder.
- 2026-10-15|Second pass: added 2026 Aging Cell dAKG cross-sectional findings and ABLE RCT watch; grade unchanged (C+) pending RCT data.